Scholar Rock (NASDAQ:SRRK) Director Katie Peng Sells 1,006 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Katie Peng sold 1,006 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $44.09, for a total value of $44,354.54. Following the completion of the transaction, the director owned 32,908 shares of the company’s stock, valued at $1,450,913.72. This trade represents a 2.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Scholar Rock Stock Performance

Shares of SRRK stock traded down $1.08 during mid-day trading on Thursday, reaching $42.93. The stock had a trading volume of 1,162,934 shares, compared to its average volume of 1,642,762. Scholar Rock Holding Corporation has a 1-year low of $22.71 and a 1-year high of $48.28. The firm has a market cap of $4.38 billion, a price-to-earnings ratio of -13.63 and a beta of 0.61. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. The business’s fifty day moving average is $36.32 and its 200-day moving average is $35.34.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period in the previous year, the business earned ($0.66) earnings per share. On average, research analysts forecast that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Hedge Funds Weigh In On Scholar Rock

Several institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP boosted its position in Scholar Rock by 124.5% during the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after purchasing an additional 2,521,022 shares in the last quarter. Holocene Advisors LP purchased a new stake in shares of Scholar Rock in the third quarter valued at approximately $91,670,000. Vestal Point Capital LP acquired a new position in shares of Scholar Rock during the 1st quarter worth approximately $41,795,000. Norges Bank purchased a new position in shares of Scholar Rock during the 2nd quarter valued at approximately $41,628,000. Finally, RA Capital Management L.P. grew its stake in Scholar Rock by 6,351.3% in the 1st quarter. RA Capital Management L.P. now owns 1,136,453 shares of the company’s stock valued at $36,537,000 after acquiring an additional 1,118,837 shares during the period. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on SRRK. Truist Financial dropped their price objective on shares of Scholar Rock from $54.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, October 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. Bank of America started coverage on shares of Scholar Rock in a report on Thursday, October 9th. They issued a “buy” rating and a $53.00 price target on the stock. JPMorgan Chase & Co. lifted their price objective on Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Finally, Jefferies Financial Group began coverage on Scholar Rock in a report on Thursday, August 21st. They issued a “buy” rating and a $50.00 price objective for the company. Four investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $48.92.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.